The use of PIB-PET as a dual pathological and functional biomarker in AD

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 3, 2012, Pages 380-385

  Forsberg, Anton ^a   Engler, Henry ^b,c,d,e   Blomquist, Gunnar ^b   Långström, Bengt ^b   Nordberg, Agneta ^a,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c University Hospital   (Uruguay)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^e Uruguayan Centre of Molecular Imaging   (Uruguay)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease (AD); Cerebral blood flow; Cerebral glucose metabolism; Mild Cognitive Impairment (MCI); PIB; Positron emission tomography (PET)

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; N METHYL 11 CARBON 2 (4' METHYLAMINOPHENYL) 6 HYDROXY BENZOTHIAZOLE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN METABOLISM; CEREBRAL GLUCOSE METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; THALAMUS;

AGED; ALZHEIMER DISEASE; AMYLOID; BENZOTHIAZOLES; BIOLOGICAL MARKERS; CARBON RADIOISOTOPES; DEOXYGLUCOSE; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW;

EID: 84856056762     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.11.006     Document Type: Article

References (53)

1. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
2. Nordberg A., Rinne J., Långström B. The use of PET in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:78-87.
3. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29:1456-1465.
4. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2008, 68:1718-1725.
5. Engler H., Santillo A.F., Wang S.X., Lindau M., Savitcheva I., Nordberg A., et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:100-106.
6. Rabinovici G.D., Furst A.J., O'Neil J.P., Racine C.A., Mormino E.C., Baker S.L., et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
7. Johansson A., Savitcheva I., Forsberg A., Engler H., Langstrom B., Nordberg A., et al. [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat. Disord. 2008, 14:345-347.
8. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB-PET. J. Neurol. Neurosurg. Psychiatry 2008, 79:1331-1338.
9. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.
10. Herholz K., Ebmeier K. Clinical amyloid imaging in Alzheimerd́s disease. Lancet Neurol. 2011, 10:667-670.
11. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997, 42:85-94.
12. Herholz K., Nordberg A., Salmon E., Perani D., Kessler J., Mielke R., et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 1999, 10:494-504.
13. Kaneko K., Kuwabara Y., Sasaki M., Ogomori K., Ichimiya A., Koga H., et al. Posterior cingulate hypoperfusion in Alzheimer's disease, senile dementia of Alzheimer type, and other dementias evaluated by three-dimensional stereotactic surface projections using Tc-99m HMPAO SPECT. Clin. Nucl. Med. 2004, 29:362-366.
14. Bradley K.M., O'Sullivan V.T., Soper N.D., Nagy Z., King E.M., Smith A.D., et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 2002, 8:1772-1781.
15. Tang B.N., Minoshima S., George J., Robert A., Swine C., Laloux P., et al. Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow. Eur. J. Nucl. Med. Mol. Imaging 2004, 11:1487-1494.
16. Nihashi T., Yatsuya H., Hayasaka K., Kato R., Kawatsu S., Arahata Y., et al. Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat. Med. 2007, 6:255-262.
17. Hirao K., Ohnishi T., Hirata Y., Yamashita F., Mori T., Moriguchi Y., et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005, 4:1014-1021.
18. Dobert N., Pantel J., Frolich L., Hamscho N., Menzel C., Grunwald F. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement. Geriatr. Cogn. Disord. 2005, 20:63-70.
19. Blomquist G., Engler H., Nordberg A., Ringheim A., Wall A., Forsberg A., et al. Unidirectional influx and net accumulation of PIB. Open Neuroimaging J. 2008, 2:114-125.
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 7:939-944.
21. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 3:303-308.
22. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004, 256:240-246.
23. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
24. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003, 46:2740-2754.
25. Minoshima S., Frey K.A., Foster N.L., Kuhl D.E. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J. Comput. Assist. Tomogr. 1995, 19:541-547.
26. Engler H., Lundberg P.O., Ekbom K., Nennesmo I., Nilsson A., Bergstrom M., et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:85-95.
27. Ng S., Villemagne V.L., Berlangieri S., Lee S.T., Cherk M., Gong S.J., et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J. Nucl. Med. 2007, 48:547-552.
28. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
29. Nordberg A., Rinne J.O., Drzezga A., Brooks D.J., Vandenberghe R., Perani D., Almkvist O., Scheinin N., Grimmer T., Okello A., Van Laere K., Hinz R., Carter S.F., Kalbe E., Herholz K. PET amyloid imaging and cognition in patients with Alzheimer's disease, mild cognitive impairment (MCI) and healthy controls: a European multicenter study. Alzheimers Dement. 2009, 5(suppl. 2).
30. Grady C.L., Haxby J.V., Schapiro M.B., Gonzalez-Aviles A., Kumar A., Ball M.J., et al. Subgroups in dementia of the Alzheimer type identified using positron emission tomography. J. Neuropsychiatry Clin. Neurosci. 1990, 2:373-384.
31. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., et al. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
32. Kadir A., Almkvist O., Forsberg A., Wall A., Engler H., Långström B., Nordberg A. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol. Aging 2012, 33. 198.e1-198.314.
33. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed. Proc. 1981, 40:2311-2316.
34. Frackowiak R.S., Pozzilli C., Legg N.J., Du Boulay G.H., Marshall J., Lenzi G.L., et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981, 104:753-778.
35. Nestor P.J., Fryer T.D., Ikeda M., Hodges J.R. Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur. J. Neurosci. 2003, 18:2663-2667.
36. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1104-1113.
37. Chetelat G., Desgranges B., De La Sayette V., Viader F., Eustache F., Baron J.C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377.
38. Arnaiz E., Jelic V., Almkvist O., Wahlund L.O., Winblad B., Valind S., et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001, 12:851-855.
39. Chetelat G., Baron J.C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003, 18:525-541.
40. Jack C., Knopman D., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
41. Kadir A., Marutle A., Gonzalez D., Schöll M., Almkvist O., Mousavi M., Mustafiz T., Darreh-Shori T., Nennesmo I., Nordberg A. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzhiemer's disease. Brain 2011, 134:301-317.
42. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., et al. 11C PIB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
43. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
44. Lowe V.J., Kemp B.J., Jack C.R., Senjem M., Weigand S., Shiung M., Smith G., Knopman D., Bradley B., Boeve B., Mullan B., Petersen R.C. Comparision of 18F-FDG and PIB PET in cognitive impairment. J. Nucl. Med. 2009, 50:878-886.
45. Meyer P.T., Hellwig S., Amtage F., Rottenburger C., Sahm U., Reuland P., Weber W.A., Hüll M. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh Compound B. J. Nucl. Med. 2011, 52:393-400.
46. Rostomian A.H., Madison C., Rabinovici G.D., Jagust W.J. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J. Nucl. Med. 2011, 52:173-179.
47. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
48. Förster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Förstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A. Regional expansion of hypometabolism in Alzheimerd́s disease follows amyloid deposition with temporal delay. Biol Psychiatry in press [Electronic publication ahead of print].
49. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
50. Dubois B., Feldman H.H., Jacova C., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
51. impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 2011, 7:270-279.
52. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011, 7:280-292.
53. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011, 7:263-269.